Please login to the form below

Not currently logged in

James Mond joins Absynth Biologics as chief medical officer

Will lead plans to develop vaccines and antibodies to tackle bacterial infections including MRSA

Absynth Biologics, the UK-based developer of vaccines and antibodies for bacterial infections, has appointed Dr James Mond as chief medical officer.

Dr Mond's previous experience in the vaccination industry includes working as a consultant to Virion Systems, where he oversaw development of a vaccine technology that was later licensed to GlaxoSmithKline (GSK).

Most recently, Dr Mond was executive vice president and chief scientific officer of Biosynexus, a biopharma company whose main focus was on developing a monoclonal antibody to prevent staphylococcal infections in children with a low birth weight.

At Absynth, Dr Mond will direct strategy and manage activities related to the company's vaccine and antibody programme to target staphylococcus aureus (S. Aureus), a bacteria whose strains include the antibiotic resistant infection MRSA.

“I am delighted to have someone of James' experience join Absynth at a time when we are reaching important milestones in our S. Aureus programmes and expect to see significant developments in building our R&D pipeline during the next few years,” said Fiona Marston, chief executive of Absynth.

29th May 2012


Featured jobs

Subscribe to our email news alerts


Add my company

Seven Stones is a creative, independent healthcare communications agency of movers and thinkers. We've been doing health differently since 1991....

Latest intelligence

Digital health
The untapped potential to transform healthcare...
When is it time to rebrand?
The Biosimilar Challenge